|
Carcinoma, Ovarian Epithelial
|
0.050 |
Biomarker
|
disease |
BEFREE |
Key inclusion criteria were prospective clinical trials examining platinum-based NACT for stage II-IV epithelial ovarian cancer.
|
31818526 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.050 |
Biomarker
|
disease |
BEFREE |
To evaluate the impact of an evidence-based triage algorithm to decide between primary debulking surgery (PDS) and neoadjuvant chemotherapy followed by interval debulking surgery (NACT/IDS) for advanced epithelial ovarian cancer (EOC).
|
31402165 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
For patients with advanced stage epithelial ovarian cancer (EOC), substantial emphasis has been placed on diagnostic tests that can discern which of two treatment options - primary cytoreductive surgery (PCS) or neoadjuvant chemotherapy followed by interval cytoreductive surgery (NACT+ICS) - optimizes patient-level outcomes.
|
29486993 |
2018 |
|
Carcinoma, Ovarian Epithelial
|
0.050 |
Biomarker
|
disease |
BEFREE |
We aimed to performed a meta-analysis and systematic review on the role of neoadjuvant chemotherapy followed by interval debulking surgery (NACT-IDS) in advanced ovarian cancer (AOC) patients.
|
29492221 |
2018 |
|
Carcinoma, Ovarian Epithelial
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
TP53 K351N mutation may be associated with induction of platinum resistance after NACT in advanced EOC.
|
24463159 |
2014 |
|
Epithelial ovarian cancer
|
0.040 |
Biomarker
|
disease |
BEFREE |
To evaluate the impact of an evidence-based triage algorithm to decide between primary debulking surgery (PDS) and neoadjuvant chemotherapy followed by interval debulking surgery (NACT/IDS) for advanced epithelial ovarian cancer (EOC).
|
31402165 |
2019 |
|
Epithelial ovarian cancer
|
0.040 |
Biomarker
|
disease |
BEFREE |
Key inclusion criteria were prospective clinical trials examining platinum-based NACT for stage II-IV epithelial ovarian cancer.
|
31818526 |
2019 |
|
Malignant neoplasm of breast
|
0.040 |
Biomarker
|
disease |
BEFREE |
The aim of our study was to estimate of different CTC subsets in breast cancer during the NACT (neoadjuvant chemotherapy).
|
29565320 |
2018 |
|
Epithelial ovarian cancer
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
For patients with advanced stage epithelial ovarian cancer (EOC), substantial emphasis has been placed on diagnostic tests that can discern which of two treatment options - primary cytoreductive surgery (PCS) or neoadjuvant chemotherapy followed by interval cytoreductive surgery (NACT+ICS) - optimizes patient-level outcomes.
|
29486993 |
2018 |
|
Breast Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
The aim of our study was to estimate of different CTC subsets in breast cancer during the NACT (neoadjuvant chemotherapy).
|
29565320 |
2018 |
|
Malignant neoplasm of breast
|
0.040 |
Biomarker
|
disease |
BEFREE |
Our findings confirm that phenotypic alterations in breast cancer occur after NACT, and that these changes are more pronounced for hormone receptors (especially PR); Significant NACT-associated alterations were not apparent for HER2/neu.
|
29146052 |
2017 |
|
Breast Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Our findings confirm that phenotypic alterations in breast cancer occur after NACT, and that these changes are more pronounced for hormone receptors (especially PR); Significant NACT-associated alterations were not apparent for HER2/neu.
|
29146052 |
2017 |
|
Malignant neoplasm of breast
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
Combination of genetic variants of ESCs gene may have a profound effect in breast cancer risk and response to NACT.
|
25223935 |
2014 |
|
Epithelial ovarian cancer
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
TP53 K351N mutation may be associated with induction of platinum resistance after NACT in advanced EOC.
|
24463159 |
2014 |
|
Breast Carcinoma
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
Combination of genetic variants of ESCs gene may have a profound effect in breast cancer risk and response to NACT.
|
25223935 |
2014 |
|
Malignant neoplasm of breast
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Although, expansion of the CAGn in the AR gene doesn't show any major effect on breast cancer risk, patients with positive AR expression, pre neoadjuvant chemotherapy, were found to be good responders and a decrease in mRNA level of AR gene related to the chemotherapy-induced apoptosis could serve as an important independent predictor of response to NACT.
|
20831839 |
2010 |
|
Breast Carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Although, expansion of the CAGn in the AR gene doesn't show any major effect on breast cancer risk, patients with positive AR expression, pre neoadjuvant chemotherapy, were found to be good responders and a decrease in mRNA level of AR gene related to the chemotherapy-induced apoptosis could serve as an important independent predictor of response to NACT.
|
20831839 |
2010 |
|
Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
However, breast and node tumor sizes before and after NACT were negatively correlated with hormone receptor conversion and positively correlated with Ki-67 conversion (P < 0.05).
|
31006089 |
2020 |
|
Kidney Calculi
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
The results obtained from the renal expression of NaDC1 could explain an adaptive mechanism to prevent the formation of kidney stones by increasing the levels of citrate, a calcium chelator.
|
30140954 |
2018 |
|
Nephrolithiasis
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
The results obtained from the renal expression of NaDC1 could explain an adaptive mechanism to prevent the formation of kidney stones by increasing the levels of citrate, a calcium chelator.
|
30140954 |
2018 |
|
Malignant Neoplasms
|
0.020 |
GeneticVariation
|
group |
BEFREE |
The aim of this study was to determine the proportion of patients with advanced ovarian and related cancers (EOC+RC), treated with neoadjuvant chemotherapy and interval debulking surgery (NACT - IDS), and to determine if there was any relationship with optimal cytoreduction rates and overall survival (OS) in a state-wide gynaecologic oncology service over time.
|
28718942 |
2017 |
|
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Surgical and survival outcomes were compared between three treatment groups: patients without high tumor dissemination (HTD) who underwent primary debulking surgery (PDS group); patients with HTD who underwent DLS (DLS group); and patients with HTD diagnosed by cytological confirmation of malignancy followed by neoadjuvant chemotherapy (NACT group).
|
28701190 |
2017 |
|
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
In addition, NaDC1 immunolabel was not detected in tumors of presumed proximal tubule origin, clear cell and papillary renal cell carcinoma, or in tumors of nonproximal tubule origin, oncocytoma and chromophobe carcinoma.
|
27927654 |
2017 |
|
Kidney Calculi
|
0.020 |
Biomarker
|
disease |
BEFREE |
We have thus identified for the first time a regulatory partner for NaDC1, and have gained novel mechanistic insight into the effect of CsA on renal citrate transport and kidney stone disease, as well as into the regulation of membrane transporters in general.
|
21257749 |
2011 |
|
Nephrolithiasis
|
0.020 |
Biomarker
|
disease |
BEFREE |
We have thus identified for the first time a regulatory partner for NaDC1, and have gained novel mechanistic insight into the effect of CsA on renal citrate transport and kidney stone disease, as well as into the regulation of membrane transporters in general.
|
21257749 |
2011 |